This platform supports innovation and product development, providing the expert insight required to optimally position health interventions. Industry partners are able to leverage Liverpool School of Tropical Medicine’s world-leading expertise in mapping and modelling of the transmission and dissemination of pathogens at a micro and macro level.
This platform offers the facilities and expertise to map and model transmission on a wide range of physiological surfaces, including utilising an in vitro humanised skin model system. This provides a biologically relevant model to address transmission to and from skin without the requirement of a human challenge system.
At the macro-scale, we are looking at the movement of pathogens in different environments. This allows us to experimentally track and support modelling of environmental shedding of bacteria and viruses and track movement through water, air or waste water systems, alongside person-to-person transmission, in a diverse range of socio-economic settings. This enables effective positioning of a broad range of health interventions including clinical, hygiene, and diagnostic products – guiding and equipping industry partners with the understanding needed to shape and position interventions to ensure optimum benefit to patient and communities.
This platform includes activity repurposing current drugs for a range of different health needs. This includes a new indication for a current drug, for use as an innovative treatment for snakebites. If successful this will be the world’s first small-molecule ambulatory antivenom treatment, which has the potential to transform the patient journey and save many lives globally.
For more information or to learn how your business can engage with this platform.
Infectious Diseases physician and Professor of Clinical Microbiology at the Liverpool School of Tropical Medicine
Professor Feasey is based at the Malawi Liverpool Wellcome Research Programme in Blantyre, Malawi. His research is focused on the surveillance and management of antimicrobial resistant bacterial infection, and taking a one health approach to exploring the transmission of enteric pathogens associated with invasive disease. His research group uses bacterial genomics, spatial statistics and transmission modelling in collaboration with the Wellcome Sanger Institute and CHICAS at the University of Lancaster.
Director of the Centre for Snakebite Research & Interventions and Chair in Tropical Disease Biology at Liverpool School of Tropical Medicine
Following completion of his doctoral studies characterising the venom composition of medically important snake species at Bangor University, Prof. Casewell worked for two years for MicroPharm Ltd leading research and clinical development of snakebite treatments known as antivenoms.